References
- Witjes JA, van der Meijden AP, Debruyne FM. Use of intravesical bacillus Calmette–Guérin in the treatment of superficial transitional cell carcinoma of the bladder: an overview. Urol Int 1990;45:129–36.
- Lamm DL. Efficacy and safety of bacille Calmette–Guérin immunotherapy in superficial bladder cancer. Clin Infect Dis 2000;31:S86–90.
- Lamm DL, van der Meijden AP, Morales A., Brosman SA, Catalona WJ, Herr HW, . Incidence and treatment of complications of bacillus Calmette–Guérin intravesical therapy in superficial bladder cancer. J Urol 1992;147: 596–600.
- Steg A, Leleu C, Debre B, Boccon-Gibod L, Sicari D. Systemic bacillus Calmette–Guérin infection, ‘BCG-itis’, in patients treated by intravesical bacillus Calmette–Guérin therapy for bladder cancer. Eur Urol 1989;16:161–4.
- Gonzales OY, Musher DM, Brar I, Furgeson S, Boktuor MR, Septimus EJ, . Spectrum of bacille Calmette–Guérin (BCG) infection after intravesical BCG immunotherapy. Clin Infect Dis 2003;36:140–8.
- Lamm DL, Torti FM. Bladder cancer. CA Cancer J Clin 1996;46:93.
- Patard JJ, Guille F, Lobel B, Abbou CC, Chopin D. Etat actuel des connaissances sur les mecanismes d'action du BCG. Prog Urol 1998;8:415–21.
- Proctor DD, Chopra S, Rubenstein SC, Jokela JA, Uhl L. Mycobacteremia and granulomatous hepatitis following initial intravesical bacillus Calmette–Guérin instillation for bladder carcinoma. Am J Gastroenterol 1993;88:1112–5.
- Rawls WH, Lamm DL, Lowe BA, Crawford ED, Sarosdy MF, Montie JE, . Fatal sepsis following intravesical bacillus Calmette–Guérin administration for bladder cancer. J Urol 1990;144:1328–30.
- Van der Meijden AP, Brausi M, Zambon V, Kirkels W, de Balincourt C, Sylvester R, . Intravesical instillation of epirubicin, bacillus Calmette–Guérin and bacillus Calmette–Guérin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J Urol 2001; 166:476–81.